Sign Merck ($MRK) CEO Ken Frazier up for the no-megamergers pledge.
Is 2013 the year that Sun Pharmaceutical Industries makes a European deal? Chairman Israel Makov tells Bloomberg that the Indian drugmaker is, in fact, scouting the region for deals.
After months of rumors, ShangPharma is pulling the trigger on a deal that will take it private, creating a parent company that unites private equity firms and some of the CRO's leadership.
BGI-Shenzhen nailed down U.S. government approval for its controversial buyout of Complete Genomics, which would expand the Chinese sequencing powerhouse's technological capabilities in the competitive business of decoding DNA for medicine and agriculture.
Perrigo has further solidified its position in topical dermatology drugs, one of the areas in which prices have been escalating of late.
Sanofi has apparently struck a deal to buy some piece or pieces of Johnson & Johnson's McNeil unit. As Bloomberg reports, the two companies have won antitrust approval for the deal--whatever it is.
Parexel International is looking to bolster its regulatory consulting business, spending $72 million on Liquent, maker of software solutions for submissions and registrations.
Covidien ($COV) capped 2012 with an agreement to snatch up CV Ingenuity, a small California company developing a drug-coated balloon designed to treat peripheral artery disease.
Rumor has it Roche is back on the hot stove and eyeing another bid for Illumina, and while analysts and journos are skeptical, the market sure seems to believe the hype. The gene sequencing company's shares jumped as much as 9.3% yesterday amid all the speculation.
Sanofi has found something to like about its prospects in India besides the country's huge population of potential drug consumers. The country also has a lot of livestock and that need drugs, too.